Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

4-Dimethylaminoazobenzene · DAB

Small molecule · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial (none active)
1 Registered trials

What is 4-Dimethylaminoazobenzene?

4-Dimethylaminoazobenzene (DAB) is a yellow crystalline azo compound that was used as a dye and pH indicator and is no longer produced in the United States. Exposure causes dermatitis, and it is reasonably anticipated to be a human carcinogen.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DAB
Drug type
Small molecule
Developer
Novartis Pharmaceuticals
In trials of
SCYX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04092725 Phase 1 Pharmacokinetics Completed SCYX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pharmacokinetics

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.